Evidence map›Paper›PMID 42182842›Full record

ArticleOpen forum infectious diseases2026

Renal Outcomes in People With HIV-1 and Renal Impairment Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide: Integrated Analysis From 9 Phase 3/3b Clinical Trials.

Frank A Post, David Wohl, Geoffroy Liegeon, Indira Brar, Debbie Hagins, Yazdan Yazdanpanah, Anchalee Avihingsanon, Hui Liu, Keith Aizen, Jason T Hindman and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Frank A PostDepartment of Inflammation Biology, School of Immunology & Microbial Sciences, King's College Hospital NHS Foundation Trust, London, UK.ORCID https://orcid.org/0000-0002-2844-1612
David WohlDivision of Infectious Diseases, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID https://orcid.org/0000-0002-7764-0212
Geoffroy LiegeonSaint-Louis Hospital, AP-HP, Université Paris Cité, Paris, France.ORCID https://orcid.org/0000-0003-1267-4347
Indira BrarInfectious Disease, Henry Ford Health, Detroit, Michigan, USA.ORCID https://orcid.org/0000-0002-0568-6457
Debbie HaginsChatham CARE Center, Savannah, Georgia, USA.ORCID https://orcid.org/0000-0001-7478-7609
Yazdan YazdanpanahBichat-Claude Bernard Hospital, AP-HP, Paris, France.ORCID https://orcid.org/0009-0004-2402-643X
Anchalee AvihingsanonHIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand.
Hui LiuClinical Development, Gilead Sciences, Inc., Foster City, California, USA.
Keith AizenClinical Development, Gilead Sciences, Inc., Foster City, California, USA.ORCID https://orcid.org/0009-0009-2763-8745
Jason T HindmanClinical Development, Gilead Sciences, Inc., Foster City, California, USA.ORCID https://orcid.org/0000-0003-1513-3423
Samir GuptaDivision of Infectious Diseases, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Among 1069 people with HIV-1 and mild to moderate renal impairment at baseline treated with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) across 9 clinical trials, renal function remained generally stable over follow-up of up to 240 weeks. Renal adverse events were infrequent, and discontinuation due to renal toxicity was rare.

Indexed as

B/F/TAFchronic kidney diseaseHIV-1renal impairmenttenofovir alafenamide

Identifiers

PMID42182842
PMCPMC13192347

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.